PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat pancreatic cancer: combo therapy targets genetic weak spot
Disease control Recruiting nowThis study tests a combination of an immunotherapy drug (cemiplimab) and chemotherapy (gemcitabine) in people with advanced pancreatic cancer that has a specific genetic change (SWI/SNF). Participants must have already tried standard chemotherapy. The goal is to see if this combo…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Blood marker may predict deadly complications after pancreatic surgery
Knowledge-focused Recruiting nowThis study is looking at whether a blood test measuring mHLA-DR can help doctors predict severe complications after surgery for pancreatic cancer. The researchers will follow 100 patients who have pancreatic surgery to see if changes in this immune marker can warn of problems lik…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated May 12, 2026 13:41 UTC